Table 2

Comparison of ETP and peak height measurements (TF0.5 pM) between controls and FXI-deficient patients divided into nonbleeder and bleeder groups

TG parameter and sample conditionsControls (n = 50)Nonbleeders (n = 50)Bleeders (n = 24)P nonbleeder vs controlP bleeder vs controlP bleeder vs nonbleeder
ETP (nM*mins)       
 PRP CTI 1020 ± 234 957 ± 262 522 ± 166 ns **** **** 
 PRP no CTI 1433 ± 215 1395 ± 294 1143 ± 420 ns ** ** 
 PPP CTI 302 ± 103 275 ± 125 209 ± 138 ns *** 
 PPP no CTI 1407 ± 223 1165 ± 414 706 ± 416 ** **** **** 
Peak height (nM)       
 PRP CTI 58.6 ± 15.3 44.2 ± 16 21.8 ± 8.1 *** **** **** 
 PRP No CTI 111 ± 22.2 89.9 ± 27.5 67.7 ± 32.4 *** **** ** 
 PPP CTI 18.2 ± 7.9 15.2 ± 9.6 9.3 ± 7.1 ns **** ** 
 PPP No CTI 335 ± 60.7 217 ± 104 105 ± 84.1 **** **** ** 
TG parameter and sample conditionsControls (n = 50)Nonbleeders (n = 50)Bleeders (n = 24)P nonbleeder vs controlP bleeder vs controlP bleeder vs nonbleeder
ETP (nM*mins)       
 PRP CTI 1020 ± 234 957 ± 262 522 ± 166 ns **** **** 
 PRP no CTI 1433 ± 215 1395 ± 294 1143 ± 420 ns ** ** 
 PPP CTI 302 ± 103 275 ± 125 209 ± 138 ns *** 
 PPP no CTI 1407 ± 223 1165 ± 414 706 ± 416 ** **** **** 
Peak height (nM)       
 PRP CTI 58.6 ± 15.3 44.2 ± 16 21.8 ± 8.1 *** **** **** 
 PRP No CTI 111 ± 22.2 89.9 ± 27.5 67.7 ± 32.4 *** **** ** 
 PPP CTI 18.2 ± 7.9 15.2 ± 9.6 9.3 ± 7.1 ns **** ** 
 PPP No CTI 335 ± 60.7 217 ± 104 105 ± 84.1 **** **** ** 

Comparison of results (mean ± standard deviation) between groups was performed using ANOVA test with the Bonferroni multiple comparison test or the Kruskal-Wallis test with Dunn’s multiple comparison test (*P < .05, **P < .01, ***P < .001, ****P < .0001).

ns, not significant.

Close Modal

or Create an Account

Close Modal
Close Modal